Immunohistochemical Expression of SOX-10 in Spindle Cell Neoplasms

Sumiti Gupta; Ajadiya Savan; Pooja Rathee; Nishtha Gupta; Nisha Marwah; Sunita Singh

doi:10.21276/apalm.3530

Authors

Sumiti Gupta Department of Pathology, PGIMS, Rohtak, India
Ajadiya Savan Department of Pathology, PGIMS, Rohtak, India
Pooja Rathee Department of Pathology, PGIMS, Rohtak, India
Nishtha Gupta Department of IHBT, GMCH, Chandigarh, India
Nisha Marwah Department of Pathology, PGIMS, Rohtak, India
Sunita Singh Department of Pathology, PGIMS, Rohtak, India

DOI:

https://doi.org/10.21276/apalm.3530

Keywords:

Spindle cell neoplasm, SOX-10, Immunohistochemistry, Benign, Malignant

Abstract

Background: Spindle cell neoplasms may range from benign to malignant tumors. This heterogenous group of lesions includes those of neural, fibroblastic, myofibroblastic, myogenic, epithelial and vascular tumors. This study was conducted to evaluate the immunohistochemical expression of SOX-10 in spindle cell neoplasms.

Materials and Methods: The study comprised of total 50 cases of spindle cell neoplasm collected over a period of one year and evaluated for SOX-10 expression using the immunohistochemistry technique.

Results: Out of 50 cases of spindle cell neoplasms, 44% were benign and 56% were malignant. Patients age ranged from 17 to 89 years with female predominance (male:female::2:3). Tumor size in maximum dimension varied from 0.3 to 15 cm with a mean diameter of 4.8 cm. SOX-10 positive immunohistochemical expression was seen in 38.0% cases. Nuclear staining of SOX-10 was evaluated according to the four-point system of Adams et al. SOX-10 expression was significantly associated with tissue/site, S100, SMA and benign spindle cell neoplasms, while no statistically significant association was seen with malignant spindle cell neoplasms.

Conclusion: The present study on spindle cell neoplasms highlights the importance of accurate diagnosis in guiding appropriate treatment.

References

1. Singh E. Spindle cell tumours of the head and neck- a taxonomic review. J. Clin. Diagnostic Res. 2018;12(12).

2. Lewis JS Jr. Spindle cell lesions-neoplastic or non-neoplastic?: spindle cell carcinoma and other atypical spindle cell lesions of the head and neck. Head Neck Pathol. 2008 2(2):103-10.

3. Surbhi, Metgud R, Naik S, Patel S. Spindle cell lesions: A review on immunohistochemical markers. J Cancer Res Ther.. 2017:13(3):412-8.

4. Falah N, Posey JE, Thorson W, Benke P, Tekin M, Tarshish B, et al. 22q11.2q13 duplication including SOX10 causes sex-reversal and peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease. Am J Med Genet A. 2017;173(4):1066-70.

5. Pingault V, Bodereau V, Baral V, Marcos S, Watanabe Y, Chaoui A, et al. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am J Hum Genet. 2013 92(5):707-24.

6. Dupin E, Calloni G, Real C, Gonçalves-Trentin A, Le Douarin NM. Neural crest progenitors and stem cells. CR Biol. 2007;330(6-7):521-9.

7. Huang X, Saint-Jeannet JP. Induction of the neural crest and the opportunities of life on the edge. Dev Biol. 2004;275(1):1-11.

8. Adams EJ, Green JA, Clark AH, Youngson JH. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol. 1999;52(1):75-7.

9. Szumera-Ciećkiewicz A, Bosisio F, Teterycz P, Antoranz A, Delogu F, Koljenović S, et al. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. Eur J Cancer. 2020:137:175-82.

10. Feng L, Wang M, Yibulayin F, Zhang H, Yang YL, Ren F, et al. Spindle cell sarcoma: a SEER population-based analysis. Sci Rep. 2018:8(1):5024.

11. Gassert FG, Gassert FT, Specht K, Knebel C, Lenze U, Makowski MR, et al. Soft tissue masses: distribution of entities and rate of malignancy in small lesions. BMC Cancer. 2021;21(1):93.

12. Nonaka D, Chiriboga L, Rubin BP. Sox 10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32(9):1291-8.

13. Miettinen M, McCue PA, Sarlomo-Rikala M, Biernat W, Czapiewski P, Kopczyński J, et al. Sox 10-a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol. 2015 39(6):826-35.

14. Yang C. Zhang L, Sanati S. SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic Carcinomas. Breast Cancer (Auckl). 2019;13:1178223419842185.

15. Kang Y, Pekmezci M, Folpe AL, Ersen A, Horvai AE. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014;27(1):55-61.

16. Bondurand N, Girard M. Pingault V, Lemort N, Dubourg O, Goossens M. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet. 2001:10(24):2783-95.

17. Tacha D. Qi W, Ra S, Bremer R, Yu C. Chu J, et al. A newly developed mouse monoclonal SOX 10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med. 2015;139(4):530-6.

18. Naujokas A, Charli-Joseph Y, Ruben BS, Yeh I, LeBoit PE, McCalmont TH, et al. SOX-10 expression in cutaneous myoepitheliomas and mixed tumors. J Cutan Pathol. 2014 41(4):353-63.